Analysis of cost avoidance from pharmacy students' clinical interventions at a psychiatric hospital

American Journal of Pharmaceutical Education

Volumn 75, Issue 1, 2011, Pages

  Campbell, Austin R ^a   Nelson, Leigh Anne ^b   Elliott, Ellie ^a   Hieber, Robin ^a   Sommi, Roger W ^b  

^a Center for Behavioral Medicine   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Clinical intervention; Cost avoidance; Experiential education; Pharmacy student; Psychiatry

Indexed keywords

ARTICLE; COST CONTROL; ECONOMICS; EDUCATION; FACTUAL DATABASE; HEALTH CARE COST; HOSPITAL PHARMACY; HUMAN; MENTAL HOSPITAL; ORGANIZATION AND MANAGEMENT; PHARMACY STUDENT; RETROSPECTIVE STUDY;

COST SAVINGS; DATABASES, FACTUAL; EDUCATION, PHARMACY; HEALTH CARE COSTS; HOSPITALS, PSYCHIATRIC; HUMANS; PHARMACY SERVICE, HOSPITAL; RETROSPECTIVE STUDIES; STUDENTS, PHARMACY;

EID: 85046980183     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: 10.5688/ajpe7518     Document Type: Review

References (35)

1. Knapp KK, Okamoto MP, Black BL. ASHP survey of ambulatory care pharmacy practice in health systems-2004. Am J Health-Syst Pharm. 2005;62(3):274-284.
2. Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003;23(1):113-132.
3. Gattis WA, Hasselbad V, Whellan DJ, et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159(16):1939-1945.
4. Taylor CT, Byrd BC, Krueger K. Improving primary care in rural Alabama with a pharmacy initiative. Am J Health-Syst Pharm. 2003;60(11):1123-1129.
5. Perez A, Doloresco F, Hoffman J, et al. Economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy. 2008;28(11):285e-323e.
6. Lee AJ, Boro MS, Knapp KK, et al. Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health-Syst Pharm. 2002;59(21):2070-2077.
7. Dorevitch A, Perl E. The impact of clinical pharmacy intervention in a psychiatric hospital. J Clin Pharm Ther. 1996;21(1):45-48.
8. Powell BJ, Ekkehard O, Sinkhorn C. Pharmacological aftercare for homogeneous groups of patients. Hosp Community Psychiatry. 1977;28(2):125-127.
9. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007;27(4):481-493.
10. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3): 267-270. Erratum: JAMA. 2000;283(10):1293.
11. Canales PI, Dorson PG, Crismon MI. Outcomes assessment of clinical pharmacy services in a psychiatric inpatient setting. Am J Health-Syst Pharm. 2001;58(14):1309-1316.
12. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reaction in hospitalized patients. Ann Pharmacother. 2000;34(12):1373-1379.
13. Hoffman JM, Meek PD, Touchette DR, et al. Transparent and reproducible reports on economic evaluations of clinical pharmacy services: a goal for the future? Amer J Health-Syst Pharm. 2009;66(5):442-444.
14. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra cost, and attributable mortality. JAMA. 1997;227(4):301-306.
15. Terceros Y, Chahine-Chakhtoura C, Malinowski JE, Rickley WF. Impact of a pharmacy resident on hospital length of stay and drug-related costs. Ann Pharmacother. 2007;41(5):742-747.
16. De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health-Syst Pharm. 2008;65(12):1161-1172.
17. Dolder C, Symanski B, Wooton T, McKinsey J. Pharmacist interventions in an inpatient geriatric psychiatry unit. Am J Health-Syst Pharm. 2008;65(19):1795-1796.
18. Finley PR, Crimson ML, Rush AJ. Evaluating the impact of pharmacists in mental health: a systemic review. Pharmacotherapy. 2003;23(12):1634-1644.
19. Finley PR, Rens HR, Pont JT, et al. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health-Syst Pharm. 2002;59(16):1518-1526.
20. Mutnick AH, Sterba KJ, Peroutka JA, Sloan NE, Beltz EA, Sorenson MK. Cost savings and avoidance from clinical interventions. Am J Health-Syst Pharm. 1997;54(4):392-396.
21. Alderman CP. A prospective analysis of clinical pharmacy interventions on an acute psychiatric inpatient unit. J Clin Pharm Ther. 1997;22(1):27-32.
22. Accreditation Council for Pharmacy Education. Accreditation Standards and Guidelines for the Professional Program Leading to the Doctor of Pharmacy Degree. Adopted 2007. http://www.acpe-accredit.org/pdf/ACPE_Revised_PharmD_Standards. Accessed December 9, 2010.
23. McCollum M, Nuffer W, Ellis SL, Turner CJ. Physician acceptance of pharmacotherapy recommendations made by pharmacy students in a rural pharmacy-based diabetes care and education clinic. Am J Pharm Educ. 2009;73(2):Article 24.
24. Mueller BA, Abel SR. Impact of college of pharmacy-based educational services within the hospital. Ann Pharmacother. 1990;24(4):422-425.
25. Brockmiller H, Abel SR, Koh-Knox CP, Birk CW. Cost impact of PharmD candidates' drug therapy recommendations. Am J Health-Syst Pharm. 1999;56(9):882-884.
26. Taylor CT, Church CO, Byrd DC. Documentation of clinical interventions by pharmacy faculty, residents, and students. Ann Pharmacother. 2000;34(78):843-847.
27. Marino J, Caballeo J, Liosent M, Hinkes R. Differences in pharmacy interventions at a psychiatric hospital: comparison of staff pharmacists, pharmacy faculty, and student pharmacists. Hosp Pharm. 2010;45(4):314-319.
28. th ed. text rev.) Washington, DC: 2000.
29. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997;277(4):307-311.
30. Nesbit TW, Shermock KM, Bobek MB, et al. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health-Syst Pharm. 2001;58(9):784-790.
31. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167(16):1752-1759.
32. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. JAMA. 1995;274(6):29-34.
33. Lazarou J, Pmeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279(15):1200-1205.
34. Patel R, Butler K, Garrett D, Badger N, Cheoun D, Hallman L. The impact of a pharmacist's participation on hospitals' rounds. Hosp Pharm. 2010;45(2):129-134.
35. Crowson K, Collette D, Dang M, Rittase N. Transformation of a pharmacy department: impact on pharmacist interventions, error prevention, and cost. The Joint Commission. J Qual Improve. 2002;28(6):324-330.